Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
Status:
Terminated
Trial end date:
2017-07-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if haplotype-mismatched HSCT is associated with an
improvement in treatment-related mortality (TRM) rate at 6 months.